(Q44410755)

2 December 2017

Estrogen alone or combined with medroxyprogesterone but not raloxifene reduce myocardial infarct size (English)

1 reference

2 December 2017

1 reference

https://api.crossref.org/works/10.1016/S0014-2999(03)01627-3

26 December 2023

author name string

Eftihia Sbarouni

1

1 reference

2 December 2017

Elias Bofilis

3

1 reference

2 December 2017

Dimitrios Th Kremastinos

5

1 reference

2 December 2017

Efstathios K. Iliodromitis

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12706470

26 December 2023

Zenon S. Kyriakides

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12706470

26 December 2023

language of work or name

English

0 references

publication date

1 April 2003

1 reference

2 December 2017

25 April 2003

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=12706470

full work available at URL

26 December 2023

https://api.elsevier.com/content/article/PII:S0014299903016273?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/S0014-2999(03)01627-3

https://api.elsevier.com/content/article/PII:S0014299903016273?httpAccept=text/plain

26 December 2023

1 reference

https://api.crossref.org/works/10.1016/S0014-2999(03)01627-3

European Journal of Pharmacology

26 December 2023

published in

1 reference

2 December 2017

467

1 reference

2 December 2017

1-3

1 reference

2 December 2017

163-168

1 reference

Inhibition of coronary artery atherosclerosis by 17-beta estradiol in ovariectomized monkeys. Lack of an effect of added progesterone

2 December 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2901627-3

Medroxyprogesterone acetate antagonizes inhibitory effects of conjugated equine estrogens on coronary artery atherosclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2901627-3

Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2901627-3

Raloxifene inhibits aortic accumulation of cholesterol in ovariectomized, cholesterol-fed rabbits

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2901627-3

Raloxifene and estrogen reduces progression of advanced atherosclerosis--a study in ovariectomized, cholesterol-fed rabbits

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2901627-3

Effects of estrogen and the selective estrogen receptor modulator raloxifene on markers of inflammation in postmenopausal women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2901627-3

Effect of postmenopausal hormones on inflammation-sensitive proteins: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2901627-3

Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2901627-3

Both raloxifene and estrogen reduce major cardiovascular risk factors in healthy postmenopausal women: A 2-year, placebo-controlled study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2901627-3

Raloxifene acutely relaxes rabbit coronary arteries in vitro by an estrogen receptor-dependent and nitric oxide-dependent mechanism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2901627-3

Hormone therapy to prevent disease and prolong life in postmenopausal women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2901627-3

Postmenopausal Estrogen and Progestin Use and the Risk of Cardiovascular Disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2901627-3

Cardiovascular effects of estrogen and lipid-lowering therapies in postmenopausal women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2901627-3

Estrogen monotherapy and combined estrogen-progestogen replacement therapy attenuate aortic accumulation of cholesterol in ovariectomized cholesterol-fed rabbits

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2901627-3

beta-Estradiol, but not alpha-estradiol, reduced myocardial necrosis in rabbits after ischemia and reperfusion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2901627-3

Different effects of estrogen and progesterone on experimental atherosclerosis in female versus male rabbits. Quantification of cellular proliferation by bromodeoxyuridine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2901627-3

Basal release of nitric oxide from aortic rings is greater in female rabbits than in male rabbits: implications for atherosclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2901627-3

Effects of estrogen replacement on the progression of coronary-artery atherosclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2901627-3

Cardiovascular effects of droloxifene, a new selective estrogen receptor modulator, in healthy postmenopausal women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2901627-3

Significant reduction of the antiatherogenic effect of estrogen by long-term inhibition of nitric oxide synthesis in cholesterol-clamped rabbits

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2901627-3

Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2901627-3

17 beta-estradiol preserves endothelial vasodilator function and limits low-density lipoprotein oxidation in hypercholesterolemic swine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2901627-3

17 beta-Estradiol prevents dysfunction of canine coronary endothelium and myocardium and reperfusion arrhythmias after brief ischemia/reperfusion.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2901627-3

Preconditioning limits myocardial infarct size in hypercholesterolemic rabbits

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2901627-3

Medroxyprogesterone attenuates estrogen-mediated inhibition of neointima formation after balloon injury of the rat carotid artery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2901627-3

Medroxyprogesterone interferes with ovarian steroid protection against coronary vasospasm

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2901627-3

Amelioration of ischemia- and reperfusion-induced myocardial injury by 17beta-estradiol: role of nitric oxide and calcium-activated potassium channels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2901627-3

Hypercholesterolemia increases endothelial superoxide anion production

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2901627-3

Sexually dimorphic response of the balloon-injured rat carotid artery to hormone treatment.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2901627-3

Hormone replacement therapy and increased plasma concentration of C-reactive protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2901627-3

Randomized, double-blind, placebo-controlled study on effects of raloxifene and hormone replacement therapy on plasma no concentrations, endothelin-1 levels, and endothelium-dependent vasodilation in postmenopausal women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2901627-3

Short-term estrogen reduces myocardial infarct size in oophorectomized female rabbits in a dose-dependent manner

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2901627-3

Hormone therapy and in-hospital survival after myocardial infarction in postmenopausal women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2901627-3

Effects of estrogen replacement on infarct size, cardiac remodeling, and the endothelin system after myocardial infarction in ovariectomized rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2901627-3

Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2901627-3

Antioxidant Protection of LDL by Physiological Concentrations of 17β-Estradiol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2901627-3

Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2901627-3

Role of tumor necrosis factor-alpha and interleukin-6 in the effects of hormone replacement therapy and raloxifene on C-reactive protein in postmenopausal women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2901627-3

Induction of calcium-dependent nitric oxide synthases by sex hormones.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2901627-3

Effects of hormone replacement therapy on reactivity of atherosclerotic coronary arteries in cynomolgus monkeys

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2901627-3

Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2901627-3

Identification of an estrogen response element activated by metabolites of 17beta-estradiol and raloxifene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2901627-3

Inhibition of LDL oxidation and myeloperoxidase dependent tyrosyl radical formation by the selective estrogen receptor modulator raloxifene (LY139481 HCL)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2901627-3

Progesterone and modulation of endothelium-dependent responses in canine coronary arteries

7 January 2021

30

1 reference

https://api.crossref.org/works/10.1016/S0014-2999(03)01627-3

26 December 2023

Identifiers

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/nugx2d5grbd7djhaogmviacllu

mapped directly with Wikidata item

30 July 2022

based on heuristic

Fatcat ID

release_nugx2d5grbd7djhaogmviacllu

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/nugx2d5grbd7djhaogmviacllu

mapped directly with Wikidata item

30 July 2022

based on heuristic

1 reference

https://api.fatcat.wiki/v0/release/nugx2d5grbd7djhaogmviacllu